Aasly JO, Johansen KK, Brønstad G, Warø BJ, Majbour NK, Varghese S et al (2014) Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci 6:248. https://doi.org/10.3389/fnagi.2014.00248

Article  CAS  PubMed Central  PubMed  Google Scholar 

Agin-Liebes J, Hickman RA, Vonsattel JP, Faust PL, Flowers X, Utkina Sosunova I et al (2023) Patterns of TDP-43 deposition in brains with LRRK2 G2019S mutations. Mov Disord 38:1541–1545. https://doi.org/10.1002/mds.29449

Article  CAS  PubMed Central  PubMed  Google Scholar 

Alessi DR, Pfeffer SR (2024) Leucine-rich repeat kinases. Annu Rev Biochem 93:261–287. https://doi.org/10.1146/annurev-biochem-030122-051144

Article  CAS  PubMed  Google Scholar 

Bailey RM, Covy JP, Melrose HL, Rousseau L, Watkinson R, Knight J et al (2013) LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol 126:809–827. https://doi.org/10.1007/s00401-013-1188-4

Article  CAS  PubMed Central  PubMed  Google Scholar 

Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB (2020) Genetics of Parkinson’s disease: an introspection of its journey towards precision medicine. Neurobiol Dis 137:104782. https://doi.org/10.1016/j.nbd.2020.104782

Article  CAS  PubMed Central  PubMed  Google Scholar 

Behere A, Thörnqvist PO, Winberg S, Ingelsson M, Bergström J, Ekmark-Lewén S (2021) Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model. J Neurosci Res 99:2525–2539. https://doi.org/10.1002/jnr.24927

Article  CAS  PubMed  Google Scholar 

Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L (2022) α-Synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology 99:195–205. https://doi.org/10.1212/wnl.0000000000200878

Article  CAS  PubMed  Google Scholar 

Bieri G, Brahic M, Bousset L, Couthouis J, Kramer NJ, Ma R et al (2019) LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathol 137:961–980. https://doi.org/10.1007/s00401-019-01995-0

Article  CAS  PubMed Central  PubMed  Google Scholar 

Blauwendraat C, Nalls MA, Singleton AB (2020) The genetic architecture of Parkinson’s disease. Lancet Neurol 19:170–178. https://doi.org/10.1016/s1474-4422(19)30287-x

Article  CAS  PubMed  Google Scholar 

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259. https://doi.org/10.1007/bf00308809

Article  CAS  PubMed  Google Scholar 

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211. https://doi.org/10.1016/s0197-4580(02)00065-9

Article  PubMed  Google Scholar 

Chiba S, Takada E, Tadokoro M, Taniguchi T, Kadoyama K, Takenokuchi M et al (2012) Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy. Neurobiol Aging 33:2491–2505. https://doi.org/10.1016/j.neurobiolaging.2011.11.002

Article  CAS  PubMed  Google Scholar 

Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A et al (2012) Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149:1048–1059. https://doi.org/10.1016/j.cell.2012.03.037

Article  CAS  PubMed Central  PubMed  Google Scholar 

Daher JP, Pletnikova O, Biskup S, Musso A, Gellhaar S, Galter D et al (2012) Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet 21:2420–2431. https://doi.org/10.1093/hmg/dds057

Article  CAS  PubMed Central  PubMed  Google Scholar 

Daher JP, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB (2014) Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci U S A 111:9289–9294. https://doi.org/10.1073/pnas.1403215111

Article  CAS  PubMed Central  PubMed  Google Scholar 

Dickson DW (2012) Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a009258

Article  PubMed Central  PubMed  Google Scholar 

Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM et al (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8:1150–1157. https://doi.org/10.1016/s1474-4422(09)70238-8

Article  CAS  PubMed  Google Scholar 

Dulski J, Ross OA, Wszolek ZK (2024) Genetics of Parkinson’s disease: state-of-the-art and role in clinical settings. Neurol Neurochir Pol 58:38–46. https://doi.org/10.5603/pjnns.97806

Article  PubMed  Google Scholar 

El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA et al (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. Faseb J 20:419–425. https://doi.org/10.1096/fj.03-1449com

Article  CAS  PubMed  Google Scholar 

Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F (2002) A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51:296–301. https://doi.org/10.1002/ana.10113

Article  CAS  PubMed  Google Scholar 

Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H et al (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57:918–921. https://doi.org/10.1002/ana.20484

Article  CAS  PubMed  Google Scholar 

Funayama M, Nishioka K, Li Y, Hattori N (2023) Molecular genetics of Parkinson’s disease: Contributions and global trends. J Hum Genet 68:125–130. https://doi.org/10.1038/s10038-022-01058-5

Article  PubMed  Google Scholar 

Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ et al (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson’s disease. J Neurosci Res 59:528–533. https://doi.org/10.1002/(sici)1097-4547(20000215)59:4%3c528::Aid-jnr8%3e3.0.Co;2-0

Article  CAS  PubMed  Google Scholar 

Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O’Neill E, Meitinger T et al (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15:223–232. https://doi.org/10.1093/hmg/ddi439

Article  CAS  PubMed  Google Scholar 

Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S (2009) Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15:300–306. https://doi.org/10.1016/j.parkreldis.2008.07.010

Article  PubMed  Google Scholar 

Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM et al (2008) Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70:1456–1460. https://doi.org/10.1212/01.wnl.0000304044.22253.03

Article  CAS  PubMed  Google Scholar 

Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 7:583–590.